The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Mosunetuzumab in B-NHL R/R to CAR-T
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, outlines recent data on mosunetuzumab, a bispecific antibody targeting both CD3 and CD20, in patients with B-cell non-Hodgkin lymphoma (NHL), who are relapsed/refractory to CAR-T therapies, or for those who do not have access to CAR-T. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
